- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:26 | Scholar Rock submits application of SMA therapy to FDA | ||
| Mi | Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies | ||
| Di | Manas AI launches to focus on cancer medicine discovery | ||
| Mo | EMA validates X4's mavorixafor application for WHIM syndrome treatment | ||
| Fr | FDA approves Amneal Pharmaceuticals' Alzheimer's and oncology treatments | ||
| 23.01. | Kamada to supply immune globulin products in Latin America | ||
| 22.01. | FDA grants fast track status to Nacuity's NPI-001 for retinitis pigmentosa | ||
| 21.01. | Health Canada authorises Roche's Vabysmo for certain eye conditions | ||
| 20.01. | Fermion and Simcere to partner on development of pain treatment drug | ||
| 17.01. | Micron Biomedical secures funds for needle-free vaccine development | ||
| 16.01. | FDA clears Axcynsis' AT03-65 IND for CLDN6-positive solid tumours | ||
| 15.01. | Cycle expands MS treatment portfolio with Banner Life Sciences acquisition | ||
| 13.01. | JW Therapeutics' Carteyva receives breakthrough therapy status for r/r LBCL | ||
| 10.01. | RheumaGen secures $15m in Series A funding to advance RA therapies | ||
| 09.01. | Parvus and Resilience expand partnership to develop IBD drug candidate | ||
| 08.01. | FDA grants priority review to Dizal's sunvozertinib NDA for NSCLC treatment | ||
| 07.01. | Star Therapeutics' von Willebrand disease therapy gains FDA fast track status | ||
| 06.01. | China's NMPA approves Astellas' advanced gastric cancer combo therapy | ||
| 03.01. | China's NMPA approves Innovent's taletrectinib for NSCLC treatment | ||
| 02.01. | Brii Biosciences acquires BRII-179 assets from VBI Vaccines | ||
| 31.12.24 | WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery | ||
| 30.12.24 | FDA approves BeiGene's TEVIMBRA combo for treating certain gastric cancers | ||
| 27.12.24 | Axcelead DDP and Astellas partner for targeted protein degrader discovery | ||
| 26.12.24 | Bio-Thera and Tabuk partner for Stelara biosimilar in Saudi Arabia | ||
| 24.12.24 | Basilea receives additional funding from CARB-X to advance antibiotic candidate |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
